Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Mometasone Furoate

FDA-approved product (ointment, topical), marketed as Asmanex Hfa, Asmanex Twisthaler, Elocon and 4 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Mometasone Furoate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Airway obstruction
  • Allergic rhinitis
  • Asthma
  • Nasal Cavity Polyp
  • Nasal congestion
  • Nasal polyposis
  • Seasonal allergic rhinitis
  • Skin disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Corticosteroids, potent (group iii); Corticosteroids, potent, other combinations; Corticosteroids; Glucocorticoids
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli35.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis36.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Mometasone Furoate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Mometasone Furoate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.

    NCT05776927 · start 2026-08-04

    Registered record
    Registry ID
    NCT05776927
    Conditions
    Asthma
    Interventions
    QVM149; Salmeterol Xinafoate / Fluticasone Propionate; Placebo to QVM149; Placebo to salmeterol xinafoate / fluticasone propionate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2026-08-04
    Completion
    2029-01-30
    Enrolment
    188

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma
    InterventionQVM149; Salmeterol Xinafoate / Fluticasone Propionate; Placebo to QVM149; Placebo to salmeterol xinafoate / fluticasone propionate
    PhasePhase 3
    Registry statusRecruiting

  • Omega-3-Based Nutraceutical Supplementation as Adjunctive Therapy in Adults With Otitis Media With Effusion: A Multicenter, Double-Blind, Randomized Placebo-Controlled Trial

    NCT07721610 · start 2025-10-01

    Registered record
    Registry ID
    NCT07721610
    Conditions
    Otits Media With Effusion
    Interventions
    Omega-3-based nutraceutical combination (Otoair Flogo); Bilastine 20 mg; Placebo Tablet or Capsule; Intranasal mometasone furoate spray; Oral deflazacort 30 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2025-10-01
    Completion
    2026-05-01
    Enrolment
    501

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOtits Media With Effusion
    InterventionOmega-3-based nutraceutical combination (Otoair Flogo); Bilastine 20 mg; Placebo Tablet or Capsule; Intranasal mometasone furoate spray +1 more
    PhasePhase 4
    Registry statusCompleted

  • Individualizing Treatment for Asthma in Primary Care (Full Study)

    NCT07052942 · start 2025-08-01

    Registered record
    Registry ID
    NCT07052942
    Conditions
    Asthma; Asthma Attack; Asthma Exacerbations
    Interventions
    Inhaled corticosteroid (ICS); Azithromycin; Asthma Symptom Monitoring Web-based Application
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-08-01
    Completion
    2029-11-15
    Enrolment
    3,200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma; Asthma Attack; Asthma Exacerbations
    InterventionInhaled corticosteroid (ICS); Azithromycin; Asthma Symptom Monitoring Web-based Application
    PhasePhase 4
    Registry statusRecruiting

  • Vibroacoustic Therapy With Oscillating Positive Expiratory Pressure in the Treatment of Nasal Congestion

    NCT07114107 · start 2025-08

    Registered record
    Registry ID
    NCT07114107
    Conditions
    Atopic Rhinitis; Atopic Asthma
    Interventions
    VPAT (Vibratory Positive Pressure Therapeutic Apparatus）; basic medications (antihistamines, mometasone furoate nasal spray, ICS-LABA; OPEP（Oscillating Positive Expiratory Pressure device）
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2025-08
    Completion
    2026-05
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtopic Rhinitis; Atopic Asthma
    InterventionVPAT (Vibratory Positive Pressure Therapeutic Apparatus）; basic medications (antihistamines, mometasone furoate nasal spray, ICS-LABA; OPEP（Oscillating Positive Expiratory Pressure device）
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study

    NCT06914908 · start 2025-05-12

    Registered record
    Registry ID
    NCT06914908
    Conditions
    Chronic Rhinosinusitis With Nasal Polyps
    Interventions
    Lunsekimig; Mometasone furoate nasal spray (MFNS)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Enrolling by invitation
    Start
    2025-05-12
    Completion
    2031-01-29
    Enrolment
    71

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Rhinosinusitis With Nasal Polyps
    InterventionLunsekimig; Mometasone furoate nasal spray (MFNS)
    PhasePhase 2
    Registry statusEnrolling by invitation

  • Comparison of Effectiveness and Safety of Triple Combination Cream of Fucinolone Acetonide 0.01%, Hydroquinone 4%, Tretinoin 0.05% with Mometasone Furoate 0.1%, Hydroquinone 4%, Tretinoin 0.05% in the Treatment of Melasma

    NCT06780644 · start 2025-02-17

    Registered record
    Registry ID
    NCT06780644
    Conditions
    Melasma
    Interventions
    Triple combination cream; Triple combination cream
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2025-02-17
    Completion
    2025-09-01
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelasma
    InterventionTriple combination cream; Triple combination cream
    PhaseNot applicable
    Registry statusNot yet recruiting

  • A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps

    NCT06834360 · start 2025-02-06

    Registered record
    Registry ID
    NCT06834360
    Conditions
    Chronic Rhinosinusitis With Nasal Polyps
    Interventions
    Itepekimab (SAR440340); Placebo; Mometasone furoate nasal spray (MFNS)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2025-02-06
    Completion
    2027-10-11
    Enrolment
    216

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Rhinosinusitis With Nasal Polyps
    InterventionItepekimab (SAR440340); Placebo; Mometasone furoate nasal spray (MFNS)
    PhasePhase 3
    Registry statusActive not recruiting

  • Combination of Oral Supplement With Fatty Acids, Vitamin B6, Perilla, and Liquorice With Nasal Steroids for the Treatment of Allergic Rhinitis

    NCT07016763 · start 2024-09-01

    Registered record
    Registry ID
    NCT07016763
    Conditions
    Allergic Rhinitis
    Interventions
    Oral fatty acid; Mometasone Furoate Nasal Spray (MFNS)
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2024-09-01
    Completion
    2025-03-01
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllergic Rhinitis
    InterventionOral fatty acid; Mometasone Furoate Nasal Spray (MFNS)
    PhaseEarly phase 1
    Registry statusCompleted

  • Role of Lung Function for Exercise Capacity in Well-trained Individuals

    NCT06077019 · start 2023-10-03

    Registered record
    Registry ID
    NCT06077019
    Conditions
    Exercise Performance
    Interventions
    Vilanterol and Fluticasone Furoate; Indacaterol and Mometasone Furoate; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2023-10-03
    Completion
    2026-12-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionExercise Performance
    InterventionVilanterol and Fluticasone Furoate; Indacaterol and Mometasone Furoate; Placebo
    PhaseNot applicable
    Registry statusRecruiting

  • Efficacy of Azelastine and Mometasone Irrigation in Comparison to Nasal Sprays in Patients With Chronic Rhinitis

    NCT05626621 · start 2022-11-23

    Registered record
    Registry ID
    NCT05626621
    Conditions
    Chronic Rhinitis
    Interventions
    Azelastine (137 mcg/spray) Nasal Spray and Mometasone (50 mcg/spray) Nasal Spray; Mometasone Nasal Irrigation (1 mg capsule); Mometasone (1 mg) and Azelastine (1 mg) Nasal Irrigation
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2022-11-23
    Completion
    2026-08
    Enrolment
    81

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Rhinitis
    InterventionAzelastine (137 mcg/spray) Nasal Spray and Mometasone (50 mcg/spray) Nasal Spray; Mometasone Nasal Irrigation (1 mg capsule); Mometasone (1 mg) and Azelastine (1 mg) Nasal Irrigation
    PhasePhase 4
    Registry statusUnknown

  • An Observational Prospective Study to Characterize Patients Initiating Enerzair® Breezhaler®, With or Without Sensor, as a Maintenance Treatment for Asthma

    NCT05120986 · start 2022-02-15

    Registered record
    Registry ID
    NCT05120986
    Conditions
    Asthma
    Interventions
    IND/GLY/MF
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Withdrawn
    Start
    2022-02-15
    Completion
    2023-05-15
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma
    InterventionIND/GLY/MF
    PhaseNot recorded
    Registry statusWithdrawn

  • Impact of RYALTRIS® Nasal Spray on Patients' Reported Outcomes

    NCT05129306 · start 2021-11-17

    Registered record
    Registry ID
    NCT05129306
    Conditions
    Allergic Rhinitis
    Interventions
    Observational
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Withdrawn
    Start
    2021-11-17
    Completion
    2022-03-14
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllergic Rhinitis
    InterventionObservational
    PhaseNot recorded
    Registry statusWithdrawn

  • 3D Printing to Improve Nasal Irrigation Outcome

    NCT06118554 · start 2021-11-01

    Registered record
    Registry ID
    NCT06118554
    Conditions
    Chronic Rhinosinusitis With Nasal Polyps; Chronic Rhinosinusitis Without Nasal Polyps
    Interventions
    Irrigation head position
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2021-11-01
    Completion
    2027-12-30
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Rhinosinusitis With Nasal Polyps; Chronic Rhinosinusitis Without Nasal Polyps
    InterventionIrrigation head position
    PhaseNot applicable
    Registry statusRecruiting

  • Digital Adherence Monitoring of Inhalative Therapy in Real- Life Conditions

    NCT04656223 · start 2020-12-17

    Registered record
    Registry ID
    NCT04656223
    Conditions
    Asthma
    Interventions
    MF/IND/GLY plus sensor system; FDC therapy
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-12-17
    Completion
    2023-01-20
    Enrolment
    434

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma
    InterventionMF/IND/GLY plus sensor system; FDC therapy
    PhaseNot recorded
    Registry statusCompleted

  • A Study to Assess the Therapeutic Effect and Safety of Adjunctive AKST4290 in Subjects With Bullous Pemphigoid

    NCT04499235 · start 2020-01-30

    Registered record
    Registry ID
    NCT04499235
    Conditions
    Pemphigoid, Bullous
    Interventions
    Mometasone furoate; AKST4290; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2020-01-30
    Completion
    2021-04-14
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPemphigoid, Bullous
    InterventionMometasone furoate; AKST4290; Placebo
    PhasePhase 2
    Registry statusTerminated